Evaluation of race as a prognostic factor in multiple myeloma. An ancillary of Southwest Oncology Group Study 8229. Patients with advanced malignancies were eligible. There were two treatment cycles; ...
Asthma is an inflammatory disease typified by airway hyperreactivity and obstruction-producing airway resistance with a reduction in air flow. [1] The mainstay of treatment of acute asthma in children ...
ORLANDO, FL—Intracoronary abciximab does not reduce rates of death or myocardial infarction (MI) compared to standard intravenous (IV) administration of the glycoprotein IIb/IIIa inhibitor in patients ...
Interim safety summary of alemtuzumab vs. chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL) This is an ASCO Meeting Abstract from the 2004 ...
The glycoprotein IIb/IIIa inhibitor abciximab given as an intracoronary rather than intravenous (IV) bolus in patients undergoing primary percutaneous coronary intervention (PCI) may improve ...
Despite its limitations, unfractionated heparin has been the standard anticoagulant used during percutaneous coronary intervention (PCI). Several small studies have suggested that intravenous ...
The therapeutic goals for treatment of hyperglycemic crises in diabetes consist of 1) improving circulatory volume and tissue perfusion, 2) decreasing serum glucose and plasma osmolality toward normal ...
People aged 16 or over at high risk of severe illness or death from sepsis in acute hospital settings have an intravenous fluid bolus within 1 hour of risk being identified, unless contraindicated.
At a recent meeting of the AAMI Healthcare Technology Safety Institute, researchers from the University of Toronto released a report that provides nine specific recommendations to reduce the risks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback